Novartis to relocate Arnhem operations to Amsterdam, 400 jobs affected

pharmafile | September 19, 2018 | News story | Manufacturing and Production, Research and Development Netherlands, Novartis, amsterdam, pahrma, pharma 

Novartis has announced it is to relocate its operations in Arnhem in the Netherlands to the capital city of Amsterdam, according to Dutch regional public broadcaster Omroep Gelderland, uprooting the site from the base it has occupied since the 1950s.

It has been reported that the reason for the move was due to the high renovation costs of the current building on the Raapopseweg. Around 400 staff currently work at the Arnhem site and all will be affected by the move, with the expectation that they will transfer to the new base of operations.

The company said that the new destination was a “logical choice”, given its close proximity to many clients and suppliers around the capital. The move is scheduled for mid-2019 and coincides with the controversial move of the European Medicines Agency to the city of Amsterdam, following the UK’s decision to leave the European Union which forced the agency to vacate its current base in London.

Jan van Dellen,  Alderman for Economic Affairs and Sport in municipality of Arnhem, lamented the news, saying the departure of a company of Novartis’ stature is never good for the city, while Ron van Gent, Regional Director at Dutch employers’ federation VNO-NCW, remarked: “We regret it very much. Novartis is an important company and it involves a large number of high-quality jobs in the Health cluster of Arnhem-Nijmegen.”

Matt Fellows

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Novartis to acquire MorphoSys AG for €2.7bn

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …

Latest content